Review

total er α (Santa Cruz Biotechnology)

Santa Cruz Biotechnology is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Santa Cruz Biotechnology total er α

(A) Thirty nine human breast carcinoma tissue samples were stained with anti-p-ERK5 (Thr218/Tyr220) and H&E, results demonstrate representative samples with histological score (H-score) 0–2. (B) Western Blot for protein expression levels of phospho- and total ERK5 <t>and</t> <t>ER-α</t> across breast cancer cell lines. (C) MCF-7 cells expressing either MEK5 (MCF7-MEK5) or empty vector were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.76 mg, 60 day release) (n = 10/group). Points represent mean tumor volume ± SEM; * significantly different from vector p<0.05; ** significantly different from vector p<0.01.

Total Er α, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 226 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/total+er+alpha+(er%CE%B1/ER%CE%B1/pmc03739787-191-15-23
Average 95 stars, based on 226 article reviews

total er α - by Bioz Stars, 2026-09

95/100 stars

Images

1) Product Images from "MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis"

Article Title: MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

Journal: PLoS ONE

doi: 10.1371/journal.pone.0069291

Figure Legend Snippet: (A) Thirty nine human breast carcinoma tissue samples were stained with anti-p-ERK5 (Thr218/Tyr220) and H&E, results demonstrate representative samples with histological score (H-score) 0–2. (B) Western Blot for protein expression levels of phospho- and total ERK5 and ER-α across breast cancer cell lines. (C) MCF-7 cells expressing either MEK5 (MCF7-MEK5) or empty vector were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.76 mg, 60 day release) (n = 10/group). Points represent mean tumor volume ± SEM; * significantly different from vector p<0.05; ** significantly different from vector p<0.01.

Techniques Used: Staining, Western Blot, Expressing, Plasmid Preparation, Injection

(A) MCF-7-vector and MCF-7-MEK5 cells were harvested for total RNA isolation and expression of ER-α mRNA determined using qRT-PCR. Data is represented as mean fold stimulated gene expression normalized to β-actin and vector cells designated as 1. Error bars represent SEM, n = 3. (B) ERE luciferase for MCF-7-vector and –MEK5 cells transiently transfected with pGL2-ERE2X-TK-luciferase plasmid and treated with E2 or vehicle for. Results represent normalized luminescence. Normalization was to vector treated with vehicle and designated as 100 (C) qRT-PCR for MCF-7-vector and –Mek5 cells was performed for E2 responsive genes PgR, SDF-1, c-MYC and Cathepsin-D following E2 treatment. Data is represented as mean fold stimulated gene expression normalized to vehicle treated MCF-7-vcetor cells designnated as 1. Error bars represent SEM, n = 3 independent experiments. (D) MTT ana;ysis of MCF-7-vector and –Mek5 cells following treatment with indicated concentrations of vehicle, ICI or Tam for 24 hours. Data are presented as mean percentage of vehicle treated samples with vehicle normalized to 100. Error bars represent S.E.M., n = 4 independent experiment. (E) Colony assay for MCF-7-vector and –Mek5 cells following treatment with DMSO (vehicle), ICI or Tam. Cells were allowed to grow for 10 days. Colonies of >50 were counted as positive. Results were normalized to percent clonogenic survival of vehicle control cells. Data represented as mean ± S.E.M., n = 4 independent experiments. *, P<0.05; **, P<0.01; ***, P<0.001.

Figure Legend Snippet: (A) MCF-7-vector and MCF-7-MEK5 cells were harvested for total RNA isolation and expression of ER-α mRNA determined using qRT-PCR. Data is represented as mean fold stimulated gene expression normalized to β-actin and vector cells designated as 1. Error bars represent SEM, n = 3. (B) ERE luciferase for MCF-7-vector and –MEK5 cells transiently transfected with pGL2-ERE2X-TK-luciferase plasmid and treated with E2 or vehicle for. Results represent normalized luminescence. Normalization was to vector treated with vehicle and designated as 100 (C) qRT-PCR for MCF-7-vector and –Mek5 cells was performed for E2 responsive genes PgR, SDF-1, c-MYC and Cathepsin-D following E2 treatment. Data is represented as mean fold stimulated gene expression normalized to vehicle treated MCF-7-vcetor cells designnated as 1. Error bars represent SEM, n = 3 independent experiments. (D) MTT ana;ysis of MCF-7-vector and –Mek5 cells following treatment with indicated concentrations of vehicle, ICI or Tam for 24 hours. Data are presented as mean percentage of vehicle treated samples with vehicle normalized to 100. Error bars represent S.E.M., n = 4 independent experiment. (E) Colony assay for MCF-7-vector and –Mek5 cells following treatment with DMSO (vehicle), ICI or Tam. Cells were allowed to grow for 10 days. Colonies of >50 were counted as positive. Results were normalized to percent clonogenic survival of vehicle control cells. Data represented as mean ± S.E.M., n = 4 independent experiments. *, P<0.05; **, P<0.01; ***, P<0.001.

Techniques Used: Plasmid Preparation, Isolation, Expressing, Quantitative RT-PCR, Luciferase, Transfection, Colony Assay

(A) MEK5 (MCF7-MEK5) or vector cells were injected into the mammary fat pad of Nu/Nu mice. Tumor growth was monitored biweekly after palpable tumor formation (n = 10/group). Points represent mean TV ± SEM; *, P<0.05; **, P<0.01. (B) Endpoint tumors from xenograft model of MCF-7-vector and MCF-7-MEK5 treated with E2 were harvested and processed for H&E staining or immunohistochemistry for ER-α or PgR levels.

Figure Legend Snippet: (A) MEK5 (MCF7-MEK5) or vector cells were injected into the mammary fat pad of Nu/Nu mice. Tumor growth was monitored biweekly after palpable tumor formation (n = 10/group). Points represent mean TV ± SEM; *, P<0.05; **, P<0.01. (B) Endpoint tumors from xenograft model of MCF-7-vector and MCF-7-MEK5 treated with E2 were harvested and processed for H&E staining or immunohistochemistry for ER-α or PgR levels.

Techniques Used: Plasmid Preparation, Injection, Staining, Immunohistochemistry

MCF-7-MEK5 cells were transfected with empty vector or ERK5 shRNA. Decreased expression of ERK5 was confirmed with (A) RT-PCR and (B) western blot analysis. (C) MCF-7-MEK5-(vector) or MCF-7-MEK5-(ERK5-shRNA) cells (5×10 5 ) were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.72 mg, 60 day release) (n = 10/group). Tumor growth was monitored daily after palpable tumor formation. Points represent mean tumor volume ± SEM; **, P<0.01. (D) RT-PCR analysis of ER-α, ER-β, AP2γ, ERK5 expression or GADPH (control) expression. Data shown is representative of analysis of three independent experiments. (E) Western blot analysis of ER-α, ER-β, AP2γ expression with GAPDH measured as control. Blots shown are representative of three independent experiments.

Figure Legend Snippet: MCF-7-MEK5 cells were transfected with empty vector or ERK5 shRNA. Decreased expression of ERK5 was confirmed with (A) RT-PCR and (B) western blot analysis. (C) MCF-7-MEK5-(vector) or MCF-7-MEK5-(ERK5-shRNA) cells (5×10 5 ) were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.72 mg, 60 day release) (n = 10/group). Tumor growth was monitored daily after palpable tumor formation. Points represent mean tumor volume ± SEM; **, P<0.01. (D) RT-PCR analysis of ER-α, ER-β, AP2γ, ERK5 expression or GADPH (control) expression. Data shown is representative of analysis of three independent experiments. (E) Western blot analysis of ER-α, ER-β, AP2γ expression with GAPDH measured as control. Blots shown are representative of three independent experiments.

Techniques Used: Transfection, Plasmid Preparation, shRNA, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Injection

Western Blot:

Article Title: Experimental Treatment of Estrogen Receptor (ER) Positive Breast Cancer with Tamoxifen and Brivanib Alaninate, a VEGFR-2/FGFR-1 Kinase Inhibitor: a potential clinical application of angiogenesis inhibitors
Article Snippet: Equal amounts (25 μg) and concentrations of protein were loaded into 4–12% Nupage Bis-tris (Invitrogen, Carlsabad, CA) gels, and transferred to nitrocellulose membranes. .. Immunoblotting was carried out with the following antibodies: Total VEGFR-2 (1:1000, rabbit polyclonal, Cell Signaling Technologies, Beverly, MA), phospho-VEGFR-2 Tyr 951 (1:200, rabbit polyclonal, Santa Cruz, Biotechnology, Santa Cruz, CA), Total FGFR-1 and Total VEGFR-3 (1:200, rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA), Total VEGFR-1 (rabbit polyclonal,1:200, Labvision, Fremont, CA), Total ER alpha (ERα) (rabbit polyclonal, 1:200, G20, Santa Cruz, Santa Cruz, CA), Phospho-ERα (rabbit monoclonal, 1: 2000, Ser 118, clone NL 44, Upstate, Billerica, MA), β-actin (mouse monoclonal, 1:30,000, Sigma-Aldrich, St. Louis, MO) .. Total RNA was extracted from frozen tumor tissues using RNA mini easy kit (Qiagen, Venlo, The Netherlands) as per the manufacturer’s instructions.

Article Title: Experimental Treatment of Estrogen Receptor (ER) Positive Breast Cancer with Tamoxifen and Brivanib Alaninate, a VEGFR-2/FGFR-1 Kinase Inhibitor: a potential clinical application of angiogenesis inhibitors
Article Snippet: Equal amounts (25 μg) and concentrations of protein were loaded into 4–12% Nupage Bis-tris (Invitrogen, Carlsabad, CA) gels, and transferred to nitrocellulose membranes. .. Immunoblotting was carried out with the following antibodies: Total VEGFR-2 (1:1000, rabbit polyclonal, Cell Signaling Technologies, Beverly, MA), phospho-VEGFR-2 Tyr 951 (1:200, rabbit polyclonal, Santa Cruz, Biotechnology, Santa Cruz, CA), Total FGFR-1 and Total VEGFR-3 (1:200, rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA), Total VEGFR-1 (rabbit polyclonal,1:200, Labvision, Fremont, CA), Total ER alpha (ERα) (rabbit polyclonal, 1:200, G20, Santa Cruz, Santa Cruz, CA), Phospho-ERα (rabbit monoclonal, 1: 2000, Ser 118, clone NL 44, Upstate, Billerica, MA), β-actin (mouse monoclonal, 1:30,000, Sigma-Aldrich, St. Louis, MO) Real time Polymerase Chain Reaction (RT-PCR) Total RNA was extracted from frozen tumor tissues using RNA mini easy kit (Qiagen, Venlo, The Netherlands) as per the manufacturer’s instructions. .. Two micrograms of total RNA was reverse transcribed using a cDNA high capacity reverse transcription kit (Applied Biosystem, Carlsbad, CA) in 20 μl of total volume, as per manufacturer’s instruction.

Real-time Polymerase Chain Reaction:

Article Title: Experimental Treatment of Estrogen Receptor (ER) Positive Breast Cancer with Tamoxifen and Brivanib Alaninate, a VEGFR-2/FGFR-1 Kinase Inhibitor: a potential clinical application of angiogenesis inhibitors
Article Snippet: Equal amounts (25 μg) and concentrations of protein were loaded into 4–12% Nupage Bis-tris (Invitrogen, Carlsabad, CA) gels, and transferred to nitrocellulose membranes. .. Immunoblotting was carried out with the following antibodies: Total VEGFR-2 (1:1000, rabbit polyclonal, Cell Signaling Technologies, Beverly, MA), phospho-VEGFR-2 Tyr 951 (1:200, rabbit polyclonal, Santa Cruz, Biotechnology, Santa Cruz, CA), Total FGFR-1 and Total VEGFR-3 (1:200, rabbit polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA), Total VEGFR-1 (rabbit polyclonal,1:200, Labvision, Fremont, CA), Total ER alpha (ERα) (rabbit polyclonal, 1:200, G20, Santa Cruz, Santa Cruz, CA), Phospho-ERα (rabbit monoclonal, 1: 2000, Ser 118, clone NL 44, Upstate, Billerica, MA), β-actin (mouse monoclonal, 1:30,000, Sigma-Aldrich, St. Louis, MO) Real time Polymerase Chain Reaction (RT-PCR) Total RNA was extracted from frozen tumor tissues using RNA mini easy kit (Qiagen, Venlo, The Netherlands) as per the manufacturer’s instructions. .. Two micrograms of total RNA was reverse transcribed using a cDNA high capacity reverse transcription kit (Applied Biosystem, Carlsbad, CA) in 20 μl of total volume, as per manufacturer’s instruction.

Image Search Results

Journal: PLoS ONE

Article Title: MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

doi: 10.1371/journal.pone.0069291

Figure Lengend Snippet: (A) Thirty nine human breast carcinoma tissue samples were stained with anti-p-ERK5 (Thr218/Tyr220) and H&E, results demonstrate representative samples with histological score (H-score) 0–2. (B) Western Blot for protein expression levels of phospho- and total ERK5 and ER-α across breast cancer cell lines. (C) MCF-7 cells expressing either MEK5 (MCF7-MEK5) or empty vector were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.76 mg, 60 day release) (n = 10/group). Points represent mean tumor volume ± SEM; * significantly different from vector p<0.05; ** significantly different from vector p<0.01.

Article Snippet: Antibodies: ER-β, APγ, and β-actin were purchased from Cell Signaling (Danvers, MA) (dilution 1∶1000) and total ER-α, ERK5, and GAPDH were purchased from Santa Cruz Biotechnology (Dallas, Texas) (dilution 1∶250).

Techniques: Staining, Western Blot, Expressing, Plasmid Preparation, Injection

Journal: PLoS ONE

Article Title: MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

doi: 10.1371/journal.pone.0069291

Figure Lengend Snippet: (A) MCF-7-vector and MCF-7-MEK5 cells were harvested for total RNA isolation and expression of ER-α mRNA determined using qRT-PCR. Data is represented as mean fold stimulated gene expression normalized to β-actin and vector cells designated as 1. Error bars represent SEM, n = 3. (B) ERE luciferase for MCF-7-vector and –MEK5 cells transiently transfected with pGL2-ERE2X-TK-luciferase plasmid and treated with E2 or vehicle for. Results represent normalized luminescence. Normalization was to vector treated with vehicle and designated as 100 (C) qRT-PCR for MCF-7-vector and –Mek5 cells was performed for E2 responsive genes PgR, SDF-1, c-MYC and Cathepsin-D following E2 treatment. Data is represented as mean fold stimulated gene expression normalized to vehicle treated MCF-7-vcetor cells designnated as 1. Error bars represent SEM, n = 3 independent experiments. (D) MTT ana;ysis of MCF-7-vector and –Mek5 cells following treatment with indicated concentrations of vehicle, ICI or Tam for 24 hours. Data are presented as mean percentage of vehicle treated samples with vehicle normalized to 100. Error bars represent S.E.M., n = 4 independent experiment. (E) Colony assay for MCF-7-vector and –Mek5 cells following treatment with DMSO (vehicle), ICI or Tam. Cells were allowed to grow for 10 days. Colonies of >50 were counted as positive. Results were normalized to percent clonogenic survival of vehicle control cells. Data represented as mean ± S.E.M., n = 4 independent experiments. *, P<0.05; **, P<0.01; ***, P<0.001.

Techniques: Plasmid Preparation, Isolation, Expressing, Quantitative RT-PCR, Luciferase, Transfection, Colony Assay

Journal: PLoS ONE

Article Title: MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

doi: 10.1371/journal.pone.0069291

Figure Lengend Snippet: (A) MEK5 (MCF7-MEK5) or vector cells were injected into the mammary fat pad of Nu/Nu mice. Tumor growth was monitored biweekly after palpable tumor formation (n = 10/group). Points represent mean TV ± SEM; *, P<0.05; **, P<0.01. (B) Endpoint tumors from xenograft model of MCF-7-vector and MCF-7-MEK5 treated with E2 were harvested and processed for H&E staining or immunohistochemistry for ER-α or PgR levels.

Techniques: Plasmid Preparation, Injection, Staining, Immunohistochemistry

Journal: PLoS ONE

Article Title: MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis

doi: 10.1371/journal.pone.0069291

Figure Lengend Snippet: MCF-7-MEK5 cells were transfected with empty vector or ERK5 shRNA. Decreased expression of ERK5 was confirmed with (A) RT-PCR and (B) western blot analysis. (C) MCF-7-MEK5-(vector) or MCF-7-MEK5-(ERK5-shRNA) cells (5×10 5 ) were injected into the mammary fat pad of Nu/Nu mice in the presence of E2 pellets (0.72 mg, 60 day release) (n = 10/group). Tumor growth was monitored daily after palpable tumor formation. Points represent mean tumor volume ± SEM; **, P<0.01. (D) RT-PCR analysis of ER-α, ER-β, AP2γ, ERK5 expression or GADPH (control) expression. Data shown is representative of analysis of three independent experiments. (E) Western blot analysis of ER-α, ER-β, AP2γ expression with GAPDH measured as control. Blots shown are representative of three independent experiments.

Techniques: Transfection, Plasmid Preparation, shRNA, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Injection

Assay development for multiplexed biomarker quantification in breast cancer. Different strategies are employed for proteins expressed at different levels (a). To prepare each assay, protein capture during immunoprecipitation is assessed by immunoblots (b). The strategy for ER, PR, and HER2 analysis utilized IP followed by SDS-PAGE to isolate the proteins of interest from the antibody (c). Biological test cases using stimulation and drug treatment in MCF7 cells are used to test the assays (d) prior to clinical implementation

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Figure Lengend Snippet: Assay development for multiplexed biomarker quantification in breast cancer. Different strategies are employed for proteins expressed at different levels (a). To prepare each assay, protein capture during immunoprecipitation is assessed by immunoblots (b). The strategy for ER, PR, and HER2 analysis utilized IP followed by SDS-PAGE to isolate the proteins of interest from the antibody (c). Biological test cases using stimulation and drug treatment in MCF7 cells are used to test the assays (d) prior to clinical implementation

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Biomarker Discovery, Immunoprecipitation, Western Blot, SDS Page

Peptides and LC-MRM transitions for monitoring breast cancer biomarkers

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Figure Lengend Snippet: Peptides and LC-MRM transitions for monitoring breast cancer biomarkers

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Sequencing

Multiplexed biomarker quantification in frozen breast tumors. Hematoxylin and eosin (H&E)-stained slides (a) should be reviewed by a board certified pathologist to verify tumor content and assess other quality metrics (e.g., stromal, immune infiltration, necrosis, inter alia). Then, LC-MRM analysis is performed on each tissue specimen for biomarker quantification, represented here as heat maps (b). Red indicates highest expression and blue the lowest, and gray indicates that the protein was not detected. In both ER and HER2 pilot studies, one positive patient (by immunohistochemistry or fluorescence in situ hybridization performed in the clinic) was not detected as positive by the mass spectrometry assays, indicating the need to include additional metrics to assess tissue quality and content within each biomarker platform

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Figure Lengend Snippet: Multiplexed biomarker quantification in frozen breast tumors. Hematoxylin and eosin (H&E)-stained slides (a) should be reviewed by a board certified pathologist to verify tumor content and assess other quality metrics (e.g., stromal, immune infiltration, necrosis, inter alia). Then, LC-MRM analysis is performed on each tissue specimen for biomarker quantification, represented here as heat maps (b). Red indicates highest expression and blue the lowest, and gray indicates that the protein was not detected. In both ER and HER2 pilot studies, one positive patient (by immunohistochemistry or fluorescence in situ hybridization performed in the clinic) was not detected as positive by the mass spectrometry assays, indicating the need to include additional metrics to assess tissue quality and content within each biomarker platform

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Biomarker Discovery, Staining, Expressing, Immunohistochemistry, Fluorescence, In Situ Hybridization, Mass Spectrometry

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Biomarker Discovery, Immunoprecipitation, Western Blot, SDS Page

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Figure Lengend Snippet: Peptides and LC-MRM transitions for monitoring breast cancer biomarkers

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Sequencing

Journal: Methods in molecular biology (Clifton, N.J.)

Article Title: Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors

doi: 10.1007/7651_2017_113

Article Snippet: ERα (DYC5715-2),PR(DYC5415-2),and HER2 (DYC1129-2) DuoSet IC ELISA kits (R&D Systems, Minneapolis, MN).

Techniques: Biomarker Discovery, Staining, Expressing, Immunohistochemistry, Fluorescence, In Situ Hybridization, Mass Spectrometry

Review

total er α (Santa Cruz Biotechnology)

Structured Review

Images

1) Product Images from "MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis"

Related Articles

Western Blot:

Real-time Polymerase Chain Reaction:

Similar Products

Image Search Results